Immunetics

About:

Immunetics, a biotechnology company, develops immunoassay and molecular probe kits and instruments for the diagnosis of infectious diseases.

Website: http://www.immunetics.com

Twitter/X: Immunetics

Top Investors: National Institute of Allergy and Infectious Diseases, National Institutes of Health, Massachusetts Life Sciences Center

Description:

Immunetics, Inc., a biotechnology company, researches and develops immunoassay and molecular probe kits and instruments for the diagnosis of infectious diseases. Its products include Miniblotter instrument system for western blot, spoligotyping, and various multi-probe membrane assays; cell adhesion flow chamber for cell-cell interaction studies; and C6 peptide Lyme ELISA, a synthetic peptide ELISA test for Lyme disease anthrax. The company's products also include QuickELISA, a blood test for anthrax infection; and QualiCode western blot assays for diseases where diagnosis is challenging. In addition, it offers QuickELISA Anthrax-PA kit, an in vitro diagnostic test for the detection of antibodies to protective antigen of anthrax in human and animal samples; and BacTx Test for the bacterial contamination of platelets. The company sells its products through distributors in Belgium, Denmark, Norway, Finland, Sweden, France, Germany, Italy, the Netherlands, Switzerland, the United Kingdom, Canada, Honduras, Brazil, Ecuador, Venezuela, Australia, China, Korea, and Taiwan. Immunetics, Inc. was founded in 1987 and is based in Boston, Massachusetts.

Total Funding Amount:

$8.06M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Boston, Massachusetts, United States

Founded Date:

1987-01-01

Founders:

Andrew Levin

Number of Employees:

51-100

Last Funding Date:

2014-03-10

IPO Status:

Private

Industries:

© 2025 bioDAO.ai